CD274 and colorectal carcinoma: Current understanding of immune-oncology has raised excitement in targeting PD-1/PD-L1 as a promising option for treating advanced/metastatic CRC expressing PD-L1 and/or harbouring microsatellite instability (MSI) (Birendra et al., 2017; Spallanzani et al., 2018).